Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital
CONCLUSION: CRT may be omitted in patients with a negative end of treatment PET scans; however, careful observation may also obviate the need for CRT in PET positive patients.PMID:37734988 | DOI:10.1016/j.clml.2023.08.021 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 21, 2023 Category: Cancer & Oncology Authors: Su Li Bhupinder Sharma Siraj Yusuf Vasiliki Michalarea Mary Gleeson Laura Hickmott Andrew Wotherspoon Ayoma D Attygalle Katherine Vroobel Simon O'Connor Yong Du Andrea Kuhnl Sunil Iyengar Dima El-Sharkawi Ian Chau David Cunningham Source Type: research
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital
CONCLUSION: CRT may be omitted in patients with a negative end of treatment PET scans; however, careful observation may also obviate the need for CRT in PET positive patients.PMID:37734988 | DOI:10.1016/j.clml.2023.08.021 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 21, 2023 Category: Cancer & Oncology Authors: Su Li Bhupinder Sharma Siraj Yusuf Vasiliki Michalarea Mary Gleeson Laura Hickmott Andrew Wotherspoon Ayoma D Attygalle Katherine Vroobel Simon O'Connor Yong Du Andrea Kuhnl Sunil Iyengar Dima El-Sharkawi Ian Chau David Cunningham Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
CONCLUSIONS: Quality measure algorithms should incorporate a risk mortality index related to leukemia vs. other tumors and benign conditions and a risk mortality index related to the treatment status of leukemia (salvage vs. frontline therapy).PMID:37730483 | DOI:10.1016/j.clml.2023.08.016 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Farhad Ravandi Courtney DiNardo Mary Alma Welch Tapan Kadia Hagop Kantarjian Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
CONCLUSIONS: Quality measure algorithms should incorporate a risk mortality index related to leukemia vs. other tumors and benign conditions and a risk mortality index related to the treatment status of leukemia (salvage vs. frontline therapy).PMID:37730483 | DOI:10.1016/j.clml.2023.08.016 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Farhad Ravandi Courtney DiNardo Mary Alma Welch Tapan Kadia Hagop Kantarjian Source Type: research
Updates in the Management of Primary Mediastinal B Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under i...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Charbel Soueidy Hampig Raphael Kourie Source Type: research
Multiple Myeloma in Young Patients: A Scoping Review
Clin Lymphoma Myeloma Leuk. 2023 Aug 28:S2152-2650(23)00277-X. doi: 10.1016/j.clml.2023.08.019. Online ahead of print.ABSTRACTData on the disease course, presenting features, outcomes, and prognosis of younger patients with multiple myeloma (MM) are lacking. Younger patients with MM have historically been considered to have better outcomes primarily based on better tolerance of treatment and lack of medical comorbidities, but the specific age range of this population has not been uniformly defined. Given the lack of consistent data reporting in patients considered to be young MM patients, we performed a scoping review to h...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Mary Steinbach Karun Neupane Muhammad Aziz Wade Lee-Smith Kelley Julian Amandeep Godara Brian McClune Amar H Kelkar Douglas Sborov Ghulam Rehman Mohyuddin Source Type: research
Updates in the Management of Primary Mediastinal B Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under i...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Charbel Soueidy Hampig Raphael Kourie Source Type: research
Multiple Myeloma in Young Patients: A Scoping Review
Clin Lymphoma Myeloma Leuk. 2023 Aug 28:S2152-2650(23)00277-X. doi: 10.1016/j.clml.2023.08.019. Online ahead of print.ABSTRACTData on the disease course, presenting features, outcomes, and prognosis of younger patients with multiple myeloma (MM) are lacking. Younger patients with MM have historically been considered to have better outcomes primarily based on better tolerance of treatment and lack of medical comorbidities, but the specific age range of this population has not been uniformly defined. Given the lack of consistent data reporting in patients considered to be young MM patients, we performed a scoping review to h...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Mary Steinbach Karun Neupane Muhammad Aziz Wade Lee-Smith Kelley Julian Amandeep Godara Brian McClune Amar H Kelkar Douglas Sborov Ghulam Rehman Mohyuddin Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
